Surgical repair patches get little attention outside the operating room, yet they matter in procedures ranging from congenital heart defect closure to hernia reconstruction. The market behind them is growing steadily as surgeons look for materials that reinforce tissue, integrate with the body, and carry fewer complications.

Market Size and Growth Projections

According to Grand View Research, the global cardiovascular and soft tissue repair patches market was valued at USD 5.2 billion in 2025. It is projected to rise from USD 5.6 billion in 2026 to USD 9.7 billion by 2033, a CAGR of 8.4%.

Application: Soft tissue repair led in 2025 with a 47.5% revenue share, supported by high-volume procedures such as hernia repair. The FDA estimates that up to 1 million hernia repairs are performed in the U.S. each year, most using surgical mesh. Cardiac repair is expected to be the fastest-growing application, with a forecast CAGR of 18.5%, driven by the ongoing need to treat congenital and acquired structural heart conditions.

Raw material: ePTFE accounted for 56.7% of revenue in 2025, valued for its strength, durability, and chemical stability. Biomaterials and tissue-engineered materials are expected to grow faster, at a 10.0% CAGR.

Region: North America held a 35.0% share in 2025, backed by a large procedural base and mature healthcare infrastructure. Asia Pacific is the fastest-growing region, at an 11.0% CAGR through 2033. The drivers are an aging population, rising cardiovascular disease burden, and expanding surgical capacity in countries such as China, India, and Japan.

Demand drivers: WHO data cited in the report puts cardiovascular disease at an estimated 19.8 million deaths globally in 2022, about 32% of all deaths. Congenital heart disease affects roughly 1.35 million newborns each year, and about a quarter of those affected need surgical or catheter-based intervention in infancy.

Want the Full Picture? The complete report covers 20+ countries, segment-level forecasts through 2033, and detailed company profiles. Download Free Sample to see the data and structure before you decide.

Prominent Technology Trends

1. Bio-integrative and regenerative patches. Permanent synthetic materials give durable reinforcement but remain in the body as foreign material. Manufacturers are developing hybrid designs that provide temporary support while the patient’s own tissue grows in. Teijin’s SYNFOLIUM is a commercial example. It combines bioabsorbable and non-bioabsorbable yarns with cross-linked gelatin, and its structure is designed to accommodate a child’s growth. It was approved in Japan in July 2023 and launched in June 2024.
2. Advanced biologic materials. Bovine pericardium remains widely used because its collagen-rich structure is flexible, strong, and conformable. Current development focuses on durability, biocompatibility, and resistance to calcification and other complications.
3. Application-specific designs. The FDA recognizes synthetic, animal-derived, absorbable, non-absorbable, and combination constructions within hernia mesh. This variety lets manufacturers tailor patches by absorption profile, handling, and the balance between reinforcement and foreign-body response, rather than relying on one material for every anatomical site.
4. A stronger safety and evidence focus. Complications such as infection, recurrence, adhesions, and mesh migration remain a restraint on adoption. As a result, long-term clinical data, post-market surveillance, and regulatory compliance increasingly shape product development.

Speak to Analyst to ask questions about the report or discuss your specific research needs.

Prominent Industry Competitors

Companies in this space are competing on material innovation, portfolio expansion, and commercial partnerships. The report profiles these key players:

• Abbott Laboratories
• Artivion, Inc.
• B. Braun
• Baxter International Inc.
• CorMatrix Cardiovascular, Inc.
• Edwards Lifesciences Corporation
• Glycar SA
• GUNZE LIMITED
• Integra LifeSciences
• Labcor
• LeMaitre Vascular, Inc.
• Maverick Biosciences Pty Ltd
• Terumo Medical Corporation
• W. L. Gore & Associates, Inc.

Recent activity shows how companies are widening their cardiovascular portfolios. In May 2026, Artivion received U.S. FDA PMA approval for its NEXUS Aortic Arch System, extending its offering in complex aortic arch disease. Going forward, competition is likely to center on biomaterial innovation, tissue compatibility, procedure-specific designs, consistent clinical outcomes, and ease of surgical handling.

The Outlook

Growth in this market rests on a stable base of cardiac and soft tissue procedures, along with a shift toward patches that heal with the body rather than simply sit in it. Companies that pair material innovation with strong clinical evidence will be best placed to capture demand, particularly in fast-growing Asia Pacific.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today